文献速递胸部肿瘤

吉非替尼联合化疗对比吉非替尼单药治疗EGFR突变非小细胞肺癌:NEJ009研究

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
PubMed 文献 · J Clin Oncol · 2019-11-04

NEJ009研究随机分配345例初诊转移性EGFR突变NSCLC患者,比较吉非替尼联合卡铂+培美曲塞与吉非替尼单药的疗效与安全性。联合组ORR和PFS均优于单药组,中位OS也显著延长,但≥3级治疗相关不良事件发生率更高,生活质量无差异。

要点

  • 联合组ORR 84% vs 67%,PFS 20.9 vs 11.9个月,HR 0.490。
  • 联合组≥3级治疗相关不良事件65.3% vs 31.0%,生活质量无差异。

核心结论

  • 吉非替尼联合卡铂+培美曲塞较吉非替尼单药改善初治晚期EGFR突变NSCLC的PFS,OS获益需进一步验证。

研究设计与样本

  • 随机对照试验,纳入345例新诊断转移性EGFR突变NSCLC患者,随机分配至吉非替尼联合卡铂+培美曲塞组或吉非替尼单药组。

主要发现

  • 联合组≥3级治疗相关不良事件发生率为65.3%,吉非替尼组为31.0%,两组生活质量无差异,联合组发生1例治疗相关死亡。

关键数值与推荐

  • 联合组≥3级治疗相关不良事件65.3% vs 31.0%。

临床怎么用

  • 对于初治晚期EGFR突变NSCLC患者,吉非替尼联合卡铂+培美曲塞可作为治疗选择,但需注意血液学毒性等≥3级不良事件发生率较高。

局限性

  • OS获益需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations; however, little is known about the efficacy and safety of this combination compared with that of standard therapy with EGFR- tyrosine kinase inhibitors alone. METHODS: We randomly assigned 345 patients with newly diagnosed metastatic NSCLC with EGFR mutations to gefitinib combined with carboplatin plus pemetrexed or gefitinib alone. Progression-free survival (PFS), PFS2, and overall survival (OS) were sequentially analyzed as primary end points according to a hierarchical sequential testing method. Secondary end points were objective response rate (ORR), safety, and quality of life. RESULTS: The combination group demonstrated a better ORR and PFS than the gefitinib group (ORR, 84% v 67% [P < .001]; PFS, 20.9 v 11.9 months; hazard ratio for death or disease progression, 0.490 [P < .001]), although PFS2 was not significantly different (20.9 v 18.0 months; P = .092). Median OS in the combination group was also significantly longer than in the gefitinib group (50.9 v 38.8 months; hazard ratio for death, 0.722; P = .021). The rate of grade ≥ 3 treatment-related adverse events, such as hematologic toxicities, in the combination group was higher than in the gefitinib group (65.3% v 31.0%); there were no differences in quality of life. One treatment-related death was observed in the combination group. CONCLUSION: Compared with gefitinib alone, gefitinib combined with carboplatin plus pemetrexed improved PFS in patients with untreated advanced NSCLC with EGFR mutations with an acceptable toxicity profile, although its OS benefit requires further validation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hosomi Y, Morita S, Sugawara S, et al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2019. PMID: 31682542. doi:10.1200/JCO.19.01488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。